gptkbp:instanceOf
|
gptkb:drug
|
gptkbp:approvalYear
|
2012
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
gptkbp:ATCCode
|
B01AF02
|
gptkbp:availableOn
|
tablet form
|
gptkbp:bioavailability
|
50%
|
gptkbp:brand
|
gptkb:Eliquis
|
gptkbp:CASNumber
|
503612-47-3
|
gptkbp:color
|
yellow
|
gptkbp:contraindication
|
active pathological bleeding
severe hepatic impairment
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
gptkbp:eliminationHalfLife
|
~12 hours
|
gptkbp:excretion
|
urine
feces
|
gptkbp:hasBoxedWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
gptkbp:hasInChIKey
|
SLQNJXNNYZZBOW-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula
|
C25H25N5O4
|
gptkbp:hasPatentExpiry
|
2026 (US)
|
gptkbp:hasPharmacodynamics
|
reduces thrombin generation and clot formation
|
gptkbp:hasPharmacokinetics
|
peak plasma concentration in 3-4 hours
|
gptkbp:hasReversalAgent
|
gptkb:andexanet_alfa
|
gptkbp:hasSMILES
|
CC1=CC=CC=C1N2C=NC3=C2N=C(NC3=O)C4=CC=CC=C4C(=O)N5CCOCC5C(=O)O
|
gptkbp:hasUNII
|
3Z9Y7UWC1V
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09145
|
gptkbp:indication
|
Treatment and prevention of deep vein thrombosis
Treatment and prevention of pulmonary embolism
Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:manufacturer
|
gptkb:Pfizer
gptkb:Bristol-Myers_Squibb
|
gptkbp:mechanismOfAction
|
gptkb:Factor_Xa_inhibitor
|
gptkbp:metabolism
|
liver (CYP3A4, CYP3A5, CYP1A2, CYP2C8, CYP2C9, CYP2J2)
|
gptkbp:molecularWeight
|
459.5 g/mol
|
gptkbp:name
|
Apixaban
|
gptkbp:pregnancyCategory
|
B (US)
|
gptkbp:proteinBinding
|
87%
|
gptkbp:PubChem_CID
|
gptkb:DB09145
10182969
8356462
CHEMBL1940625
D09714
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
|
gptkbp:synonym
|
BMS-562247-01
|
gptkbp:target
|
gptkb:Factor_Xa
|
gptkbp:bfsParent
|
gptkb:UHOVQNZJYSORNB-UHFFFAOYSA-N
|
gptkbp:bfsLayer
|
7
|